Binding of urinary protein C inhibitor to fibrin(ogen) and its binding mechanism.
The region and mechanism of urinary protein C inhibitor (PCI) binding to fibrin(ogen) were examined using fibrin(ogen)-Sepharose and ligand blotting. Urinary PCI bound to fibrin(ogen)-Sepharose in a heparin-dependent manner at a level about 1.6-fold higher to fibrin-Sepharose than to fibrinogen-Sepharose. Scatchard analysis of the binding between urinary PCI and fibrin(ogen)-Sepharose showed that the Kd for fibrin-Sepharose and fibrinogen-Sepharose were 4.0 nM and 5.7 nM respectively. Ligand blotting using urinary PCI and an enzyme-linked immunoassay showed that urinary PCI bound to fibrinogen, fibrinogen degradation products (X, Y, D and E) and the A alpha-, B beta- and gamma-chains of fibrinogen. Binding between urinary PCI and fibrin(ogen)-Sepharose was slightly suppressed (16%) by alpha-methylmannose and largely suppressed (42%) by EACA, which indicates that the carbohydrate chain and the lysine binding site participate in the binding. These findings suggest that urinary PCI binds to fibrin(ogen) via the A alpha-, B beta- and gamma-chains and its binding is partly mediated by carbohydrate and the lysine binding site.
Hayashi
S
S
Thrombosis Chemical Institute, Tokyo, Japan.
Yamada
K
K
D015119:Aminocaproic Acid / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects; D005337:Fibrin / Q000378:metabolism*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis; D006801:Humans; D008024:Ligands; D008766:Methylmannosides / Q000494:pharmacology; D015849:Plasminogen Inactivators / Q000378:metabolism*; D018046:Protein C Inhibitor
D005338:Fibrin Fibrinogen Degradation Products; D008024:Ligands; D008766:Methylmannosides; D015849:Plasminogen Inactivators; D018046:Protein C Inhibitor; C008466:methylmannoside; D005337:Fibrin; D005340:Fibrinogen; D015119:Aminocaproic Acid